Effect of metformin monotherapy on serum lipid profile in statin-naïve individuals with newly diagnosed type 2 diabetes mellitus: a cohort study

Cardiovascular disease is a major cause of mortality and morbidity in people with type 2 diabetes mellitus (T2DM). Studies have consistently identified dyslipidemia as an important risk factor for the development of macrovascular disease. The landmark United Kingdom Prospective Diabetes Study has sh...

Full description

Saved in:
Bibliographic Details
Published in:PeerJ (San Francisco, CA) CA), 2018-04, Vol.6, p.e4578-e4578, Article e4578
Main Authors: Lin, Szu Han, Cheng, Po Chung, Tu, Shih Te, Hsu, Shang Ren, Cheng, Yun Chung, Liu, Yu Hsiu
Format: Article
Language:English
Subjects:
Age
Blood tests
Body weight
Cardiovascular disease
Cardiovascular diseases
Cholesterol
Cohort analysis
Diabetes
Diabetes and Endocrinology
Diabetes mellitus
Diabetes mellitus (non-insulin dependent)
Drug dosages
Dyslipidemia
Endocrinology
Enrollments
Hemoglobin
High density lipoprotein
Insulin
Internal medicine
Kinases
Lipids
Low density lipoprotein
Medicine
Metabolic Sciences
Metabolism
Metabolites
Metformin
Morbidity
Overweight
Statins
Triglycerides
Type 2 diabetes mellitus
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Cardiovascular disease is a major cause of mortality and morbidity in people with type 2 diabetes mellitus (T2DM). Studies have consistently identified dyslipidemia as an important risk factor for the development of macrovascular disease. The landmark United Kingdom Prospective Diabetes Study has shown that metformin therapy reduces cardiovascular events in overweight people with T2DM. This study investigates the effect of metformin monotherapy on serum lipid profile in statin-naïve individuals with newly diagnosed T2DM, and whether the effect, if any, is dosage-related. This cohort study enrolled individuals exceeding 20 years of age, with recent onset T2DM, who received at least 12 months of metformin monotherapy and blood tests for serum lipid at 6-month intervals. Exclusion criteria involved people receiving any additional antidiabetic medication or lipid-lowering drug therapy. Lipid-modifying effect of metformin was recorded as levels of serum triglycerides (TG), high density lipoprotein cholesterol (HDL-C), and low density lipoprotein cholesterol (LDL-C) measured at six month intervals. The study enrolled 155 participants with a mean age of 58.6 years and average glycosylated hemoglobin A of 8%. After initiating metformin therapy, LDL-C was significantly reduced from 111 mg/dl to 102 mg/dL at 6 months (  
ISSN:2167-8359
2167-8359
DOI:10.7717/peerj.4578